A century-old drug that failed in its original intent to treat tuberculosis but has worked well as an antileprosy medicine now holds new promise as a potential therapy for multiple sclerosis and other autoimmune diseases.
While cautioning that their findings still must be evaluated in humans, University of California, San Francisco and Stanford University Medical Center researchers report that the cholesterol-lowering drug atorvastatin (Lipitor) significantly improved, prevented relapses or reversed paralysis in mice with an experimental disease that closely resembles multiple sclerosis. The study, reported in the November 7 issue of Nature, was conducted in mice with experimental autoimmune encephalomyelitis (EAE), the standard animal model for multiple sclerosis.